Hire E A, Samson M K, Fraile R J, Baker L H
Cancer Clin Trials. 1979 Winter;2(4):293-5.
VM-26 was administered to 13 patients with metastatic adenocarcinoma of the kidney. Twelve of the 13 patients were assessable. The remaining patient was nonevaluable due to early death as defined in the protocol. No responses were observed in any of the 12 patients. Nonhematological toxicity was mild except for one instance of life-threatening hypotension, occurring during the infusion of VM-26. Significant leukopenia (less than 3000/mm3) occurred in 29% of courses and significant thrombocytopenia (less than 100,000/mm3) occurred in 14% of courses. Further studies using VM-26 in renal cell carcinoma do not seem warranted.
13例肾转移性腺癌患者接受了威猛（VM-26）治疗。13例患者中有12例可进行评估。其余1例患者因在方案规定的时间内过早死亡而无法评估。12例患者中均未观察到反应。除1例在输注VM-26期间出现危及生命的低血压外，非血液学毒性较轻。29%的疗程出现显著白细胞减少（低于3000/mm³），14%的疗程出现显著血小板减少（低于100,000/mm³）。似乎没有必要进一步开展使用VM-26治疗肾细胞癌的研究。
